139 related articles for article (PubMed ID: 38340111)
1. Combination of Acute and Maintenance Esketamine Treatment With Adjunctive Long-Term Vagus Nerve Stimulation in Difficult-to-Treat Depression.
Kavakbasi E; Baune BT
Neuromodulation; 2024 Jun; 27(4):766-773. PubMed ID: 38340111
[TBL] [Abstract][Full Text] [Related]
2. Impact of Adjunctive VNS on Drug Load, Depression Severity, and Number of Neuromodulatory Maintenance Treatments.
Kavakbasi E; Bauermeister H; Lemcke L; Baune BT
Brain Sci; 2024 Feb; 14(2):. PubMed ID: 38391733
[TBL] [Abstract][Full Text] [Related]
3. Vagus nerve stimulation as adjunctive therapy in patients with difficult-to-treat depression (RESTORE-LIFE): study protocol design and rationale of a real-world post-market study.
Young AH; Juruena MF; De Zwaef R; Demyttenaere K
BMC Psychiatry; 2020 Sep; 20(1):471. PubMed ID: 32993573
[TBL] [Abstract][Full Text] [Related]
4. Rapid titration protocol - Experiences with a dynamic novel titration regime for vagus nerve stimulation in a group of depressive patients.
Moeller S; Wang R; Aydin M; Lam AP; Sitter A; Grüter J; Philipsen A; Müller HHO
J Clin Neurosci; 2020 Apr; 74():262-264. PubMed ID: 31447363
[TBL] [Abstract][Full Text] [Related]
5. Chronic Vagus Nerve Stimulation Significantly Improves Quality of Life in Treatment-Resistant Major Depression.
Conway CR; Kumar A; Xiong W; Bunker M; Aaronson ST; Rush AJ
J Clin Psychiatry; 2018 Aug; 79(5):. PubMed ID: 30152645
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
[TBL] [Abstract][Full Text] [Related]
7. A 5-Year Observational Study of Patients With Treatment-Resistant Depression Treated With Vagus Nerve Stimulation or Treatment as Usual: Comparison of Response, Remission, and Suicidality.
Aaronson ST; Sears P; Ruvuna F; Bunker M; Conway CR; Dougherty DD; Reimherr FW; Schwartz TL; Zajecka JM
Am J Psychiatry; 2017 Jul; 174(7):640-648. PubMed ID: 28359201
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3.
Ochs-Ross R; Daly EJ; Zhang Y; Lane R; Lim P; Morrison RL; Hough D; Manji H; Drevets WC; Sanacora G; Steffens DC; Adler C; McShane R; Gaillard R; Wilkinson ST; Singh JB
Am J Geriatr Psychiatry; 2020 Feb; 28(2):121-141. PubMed ID: 31734084
[TBL] [Abstract][Full Text] [Related]
9. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
Wajs E; Aluisio L; Holder R; Daly EJ; Lane R; Lim P; George JE; Morrison RL; Sanacora G; Young AH; Kasper S; Sulaiman AH; Li CT; Paik JW; Manji H; Hough D; Grunfeld J; Jeon HJ; Wilkinson ST; Drevets WC; Singh JB
J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32316080
[TBL] [Abstract][Full Text] [Related]
10. Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data.
Nijs M; Wajs E; Aluisio L; Turkoz I; Daly E; Janik A; Borentain S; Singh JB; DiBernardo A; Wiegand F
Int J Neuropsychopharmacol; 2020 Jul; 23(7):426-433. PubMed ID: 32270176
[TBL] [Abstract][Full Text] [Related]
11. The effects of vagus nerve stimulation on the course and outcomes of patients with bipolar disorder in a treatment-resistant depressive episode: a 5-year prospective registry.
McAllister-Williams RH; Sousa S; Kumar A; Greco T; Bunker MT; Aaronson ST; Conway CR; Rush AJ
Int J Bipolar Disord; 2020 May; 8(1):13. PubMed ID: 32358769
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of vagus nerve stimulation for severe treatment-resistant major depression in clinical practice after FDA approval: outcomes at 1 year.
Cristancho P; Cristancho MA; Baltuch GH; Thase ME; O'Reardon JP
J Clin Psychiatry; 2011 Oct; 72(10):1376-82. PubMed ID: 21295002
[TBL] [Abstract][Full Text] [Related]
13. Long-term Sustained Cognitive Benefits of Vagus Nerve Stimulation in Refractory Depression.
Desbeaumes Jodoin V; Richer F; Miron JP; Fournier-Gosselin MP; Lespérance P
J ECT; 2018 Dec; 34(4):283-290. PubMed ID: 29870432
[TBL] [Abstract][Full Text] [Related]
14. Setting Up a Successful Vagus Nerve Stimulation Service for Patients With Difficult-to-Treat Depression.
Kraus C; Quach D; Sholtes DM; Kavakbasi E; De Zwaef R; Dibué M; Zajecka J; Baune BT
Neuromodulation; 2022 Apr; 25(3):316-326. PubMed ID: 35123881
[TBL] [Abstract][Full Text] [Related]
15. Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery-Åsberg Depression Rating Scale and the 9-item Patient Health Questionnaire.
Kern Sliwa J; Naranjo RR; Turkoz I; Petrillo MP; Cabrera P; Trivedi M
CNS Spectr; 2024 Jun; 29(3):176-186. PubMed ID: 38557430
[TBL] [Abstract][Full Text] [Related]
16. Vagus nerve stimulation allows to cease maintenance electroconvulsive therapy in treatment-resistant depression: a retrospective monocentric case series.
Aboubakr O; Domenech P; Heurtebise I; Gaillard R; Guy-Rubin A; Carron R; Duriez P; Gorwood P; Vinckier F; Pallud J; Zanello M
Front Psychiatry; 2023; 14():1305603. PubMed ID: 38352166
[TBL] [Abstract][Full Text] [Related]
17. Baseline characteristics of a European patient population with difficult-to-treat depression (RESTORE-LIFE) treated with adjunctive vagus nerve stimulation.
Demyttenaere K; Costa T; Kavakbasi E; Jiang M; Scheltens A; Dibué M; Hall BE; Andrade P; McAllister-Williams RH; Baune BT; Young AH
J Affect Disord; 2024 Jan; 344():284-291. PubMed ID: 37838271
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
[TBL] [Abstract][Full Text] [Related]
19. Hippocampal Gray Volumes Increase in Treatment-Resistant Depression Responding to Vagus Nerve Stimulation.
Perini GI; Toffanin T; Pigato G; Ferri G; Follador H; Zonta F; Pastorelli C; Piazzon G; Denaro L; Rolma G; Ermani M; DʼAvella D
J ECT; 2017 Sep; 33(3):160-166. PubMed ID: 28658013
[TBL] [Abstract][Full Text] [Related]
20. Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder".
Borentain S; Desai P; Fu DJ; Nancy Chen L; Lane R; Mathews M; Canuso CM
J Psychopharmacol; 2023 Aug; 37(8):836-844. PubMed ID: 36218274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
